bgp-15

Small moleculeexperimental

Clinical trial activity

1 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 2010 (NCT01069965)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

N=C(NOCC(O)CN1CCCCC1)c1cccnc1
Mol. weight
278.36 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bgp 15
  • bgp-15
  • bgp-15
  • bgp-15
  • o-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01069965Phase 2Oct 1, 2010Barc NV, Drug Research Center, Balatonfured, Hungary, Georgetown University, Integrium, Kinexum LLC, Msource Medical Development GmbH, N-Gene Research Laboratories, Inc., Thermo Fisher Scientific, University of Cologne
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Barc NVFor profit1012010
Drug Research Center, Balatonfured, HungaryFor profit1012010
Georgetown UniversityAcademic/Hospital1012010
IntegriumFor profit1012010
Kinexum LLCFor profit1012010
Msource Medical Development GmbHFor profit1012010
N-Gene Research Laboratories, Inc.For profit1112010
Thermo Fisher ScientificFor profit1012010
University of CologneAcademic/Hospital1012010
9 organizations
Page 1 / 1